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Background: Chronic pain affects nearly 116 million American adults at an estimated cost of up to $635 billion
annually and is the No. 1 condition for which patients seek care at integrative medicine clinics. In our Study on
Integrative Medicine Treatment Approaches for Pain (SIMTAP), we observed the impact of an integrative approach
on chronic pain and a number of other related patient-reported outcome measures.
Methods: Our prospective, non-randomized, open-label observational evaluation was conducted over six months,
at nine clinical sites. Participants received a non-standardized, personalized, multimodal approach to chronic pain.
Validated instruments for pain (severity and interference levels), quality of life, mood, stress, sleep, fatigue, sense of
control, overall well-being, and work productivity were completed at baseline and at six, 12, and 24 weeks. Blood
was collected at baseline and week 12 for analysis of high-sensitivity C-reactive protein and 25-hydroxyvitamin D
levels. Repeated-measures analysis was performed on data to assess change from baseline at 24 weeks.
Results: Of 409 participants initially enrolled, 252 completed all follow-up visits during the 6 month evaluation.
Participants were predominantly white (81%) and female (73%), with a mean age of 49.1 years (15.44) and an
average of 8.0 (9.26) years of chronic pain. At baseline, 52% of patients reported symptoms consistent with
depression. At 24 weeks, significantly decreased pain severity (−23%) and interference (−28%) were seen. Significant
improvements in mood, stress, quality of life, fatigue, sleep and well-being were also observed. Mean
25-hydroxyvitamin D levels increased from 33.4 (17.05) ng/mL at baseline to 39.6 (16.68) ng/mL at week 12.
Conclusions: Among participants completing an integrative medicine program for chronic pain, significant
improvements were seen in pain as well as other relevant patient-reported outcome measures.
Trial Registration: ClinicalTrials.gov, NCT01186341
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Musculoskeletal disordersBackground
A 2011 Institute of Medicine report, Relieving Pain in
America, estimates that chronic pain affects nearly 116
million American adults, a staggering number that sur-
passes those affected by heart disease, cancer, and diabetes
combined [1]. The report concludes that chronic pain costs* Correspondence: dabrams@hemeonc.ucsf.edu
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reproduction in any medium, provided the orbetween $560 billion and $635 billion annually in medical
expenses and lost productivity. Although there have been
some therapeutic advances, many patients with chronic
pain become resistant to conventional medical treatments
or suffer adverse effects from widely used prescription med-
ications with high addictive potential, such as non-steroidal
anti-inflammatory agents or opiates. For these reasons,
patients with chronic pain frequently seek to integrate
complementary therapies, often without the knowledge
of their primary care provider [2-4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and addresses the full range of physical, emotional, mental,
social, spiritual, and environmental influences that affect a
person’s health [5]. Employing a personalized strategy
that considers the patient’s unique conditions, needs,
and circumstances, integrative medicine uses the most
appropriate interventions from an array of scientific
disciplines to heal illness and help people regain and
maintain optimum health. Because integrative medicine is a
“whole systems” approach that employs multiple modalities
in concert as opposed to an isolated complementary
therapy, studying outcomes is more challenging than
evaluating an isolated pharmaceutical or botanical inter-
vention. Chronic pain is one of the main reasons patients
seek care at integrative medicine clinics [6,7].
In an effort to capture data on patient-reported out-
comes in integrative medicine, a number of leading in-
tegrative medicine clinics have collaborated to form
the first practice-based research network in the field:
the Bravewell Integrative Medicine Research Network
(BraveNet). BraveNet’s initial project was to characterize
4182 patients seeking care at nine clinical sites in a system-
atic fashion by collecting information at a single time
point [6]. This repository of data confirmed the high
utilization of integrative medicine by chronic pain patients
and informed the present Study on Integrative Medicine
Treatment Approaches for Pain (SIMTAP). We report
the impact of a six-month integrative approach on chronic




Using a prospective, non-randomized, open-label observa-
tional design, we assessed patients at baseline and six-, 12-,
and 24-week visits. At baseline, participants completed
a demographic questionnaire as well as the instruments
utilized to assess outcomes over the duration of the study.
Within a week of each projected follow-up data collection
visit, participants were asked to complete the battery of
questionnaires collected at baseline. Information on inte-
grative interventions, prescription medications, and vita-
mins and supplements utilized was collected at each study
visit. Questions about integrative modalities being utilized
were answered at weeks six, 12, and 24 to define the scope
of the interventions received.
Setting and participants
Eligible patients were enrolled at each of the nine BraveNet
clinical sites. Participants were clinic patients aged 18 or
older who were seeking their initial treatment at the center
for chronic pain, defined as persisting for at least the past
three months with an average level over the past month of
at least 4 of 10 on a numerical rating scale. Participantsprovided written informed consent before initiation of any
study-related procedures. The protocol was approved by
the Institutional Review Board at each participating site
including Allina Health Institutional Review Board; Beth
Israel Medical Center Human Subjects Protection Office
Institutional Review Board; Duke University Health
Systems Institutional Review Board; The Scripps Clinic
Institutional Review Board; Thomas Jefferson University
Division of Human Subjects Protection; University of
California Los Angeles Institutional Review Board;
University of California San Francisco Committee on
Human Research; and University of Maryland Institutional
Review Board.
Intervention
In keeping with the integrative medicine philosophy of
individualized patient-centered care, no standardized
prespecified clinical intervention for chronic pain was
prescribed for all study participants. Instead, practitioners
at each of the network sites devised treatment plans for
participating chronic pain patients. All BraveNet sites
include integrative physicians, acupuncturists, mindfulness
instructors, and yoga instructors; some also incorporate
massage therapists, manual medicine therapists, fitness/
movement specialists, dietician/nutritionists, psychologists,
healing touch therapists, and other energy practitioners.
Outcomes and follow-up
The battery of validated outcome measurements collected
at each visit included the Brief Pain Inventory (BPI) [8],
the 12-Item Short Form Health Survey (SF-12v2) [9],
the Center for Epidemiologic Studies Depression Scale
(CES-D) [10], the Perceived Stress Scale-4 (PSS-4) [11], the
Arizona Integrative Outcomes Scale (AIOS) [12], and the
Work Productivity and Activity Impairment (WPAI) survey
[13]. In addition, numerical rating scales were utilized
to assess fatigue, restfulness of sleep, and sense of con-
trol. Venipuncture for determination of high-sensitivity
C-reactive protein (hs-CRP) (a marker of inflammation)
and 25-hydroxyvitamin D levels (potentially associated
with pain syndromes) was performed at baseline and
week 12.
Statistical analysis
An objective of this network study was to demonstrate
that the sites could enroll and follow patients over a
24-week period and collect serial laboratory specimens. For
this analysis, we focus on those participants who completed
the entire 24-week program. A post hoc sensitivity analysis
was performed to determine potential differences be-
tween enrolled patients completing all four study visits
(“completers”) and those who completed at least the
baseline visit but not the entire study (“noncompleters”).
Comparisons of baseline characteristics were assessed







Age, y 48.6 (15.18) 49.8 (15.89) .44
Female 74.1% 71.1% .57
BMI (kg/m2) 25.8 (5.49) 25.9 (6.42) .81
Duration of pain, y 8.6 (9.34) 6.9 (9.04) .06
CES-D (0c–60) 17.9 (10.49) 18.3 (10.46) .71
PSS-4 (0c–16) 6.7 (3.14) 6.4 (3.17) .37
SF-12v2 mental (0–100c) 43.5 (10.43) 44.3 (11.17) .47
SF-12v2 physical (0–100c) 37.7 (10.24) 36.8 (10.82) .40
BPI Severity (0c–10) 4.6 (1.86) 4.9 (1.86) .11
BPI Interference (0c–10) 4.6 (2.58) 4.7 (2.47) .67
BMI body mass index, BPI Brief Pain Inventory, CES-D Center for Epidemiologic
Studies Depression Scale, PSS-4 Perceived Stress Scale-4, SF-12v2 12-Item Short
Form Health Survey.
aValues shown are means (SD).
bP value indicates significant difference between groups if < .05.
cIndicates better health.
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tests for categorical measures.
Descriptive statistics were summarized using frequencies
(percentages) for categorical variables. Means, standard
deviations, medians, quartiles, minimums, and maximums
were reported for all continuous variables.
Pain and quality-of-life scales
Repeated-measures analyses of variance were performed on
study completers to detect changes in BPI subscales—Pain
Severity and Interference—over time as well as changes in
quality-of-life scores. Results are summarized with a point
estimate of mean change in the outcome measures between
baseline and any specified follow-up visit with 95% confi-
dence intervals. P values are reported for overall model
summary, indicating any difference between any two given
points between baseline and 24 weeks. If the P value was
significant (<.05), follow-up linear regression analyses were
done to verify that the trends were consistent in direction
throughout all study visits, indicating constant improve-
ment or decline from visit to visit.
A secondary sensitivity analysis was done to determine
the impact of including only study completers for the
primary outcome—BPI Pain Severity and Interference
scores—instead of using the more conservative method of
last observation carried forward. The repeated-measures
analysis for the BPI Pain Severity and Interference scores
was run on three subgroups of the sample assuming that
values at missed visits were carried forward from the last
nonmissing study visit: (1) all enrolled patients, (2) patients
completing at least one postbaseline study visit, and (3)
patients completing all follow-up study visits.
Multivariate logistic regression analysis was performed
to look at variables that influenced the pain response.
Responders were defined as those with at least a 20%
decrease in the BPI interference score over 24 weeks.
Variables included in the model were age, gender, ethnicity
(Hispanic or non-Hispanic), years with chronic pain, body
mass index, and baseline values for the BPI interference
score, SF-12 physical component score, SF-12 mental
component score, CES-D score, and PSS-4.
Lab measures (hs-CRP and Vitamin D)
We used dependent t-tests to determine whether the 12-
week study visit laboratory measures differed significantly
when compared to baseline values. A P value of < .05 was
considered to indicate statistical significance.
Results
A total of 409 participants were consented and enrolled at
the nine BraveNet sites between June 2009 and November
2010. The number of participants contributing baseline
data per site ranged from 22 to 65 (median: 49). Of
the participants, 252 completed all study assessmentsduring the 24-week study and are the basis of our pri-
mary analysis.
Table 1 provides baseline demographics of the study
completers compared with those who did not contribute
data at the 24-week visit. Regardless of completion
status, the majority of the participants were women, on
average nearly 50 years of age and slightly overweight,
who reported experiencing pain for about nine years
(completers) or seven years (noncompleters). Other than
the duration of pain, completers and noncompleters
were similar in demographics and baseline scores on all
patient-reported outcomes measured. Subsequent results
are presented for the completers only.
Fifty-one percent of the participants reported pain in
the neck, 49% lumbar spine, 46% shoulder, 37% hip, 36%
knee, 32% sacrum, 31% head, 26% leg, 25% buttock,
25% thoracic spine, and 23% foot. Multiple sites could
be selected.
At week 24, participants were receiving a wide range
of modalities in their prescribed integrative suite of
therapies (see Table 2). Figure 1 is a mosaic plot of the
modalities utilized over the course of the study. The
highest number of patients received 4 modalities (N = 55),
including acupuncture/Chinese medicine (51.9%), ma-
nipulation therapy (17.3%), mind/body techniques (7.7%),
integrative medicine consult (7.7%), exercise (7.7%), yoga
(1.9%), and alternative medical systems therapy (5.8%).
Overall, acupuncture/Chinese medicine, manipulation
therapy, and mind/body therapy were the most commonly
received modalities.
Current pain medications reported at week 24 included
ibuprofen (45%), acetaminophen (32%), naproxen (20%),
triptans (18%), hydrocodone (13%), aspirin (11%), and
Table 2 Current integrative medicine pain treatments at
24 weeks for completers (N = 252)
Integrative modality groupa Patients Percentage
Acupuncture/TCM 115 47.3%
Manipulation Therapy 51 21.0%
Mind/Body 27 11.1%
Integrative Medicine Consult 25 10.3%
Exercise 12 4.9%
Yoga 6 2.5%
Alternative Medical Systems 6 2.5%
Energy Therapy 1 0.4%
a Individual integrative medicine modalities were grouped into eight
categories. Acupuncture/TCM: acupuncture, traditional Chinese medicine,
tai chi; Manipulation therapy: chiropractic, osteopathy, massage; Mind/Body:
biofeedback, deep breathing exercises, hypnosis, meditation, prayer for health,
progressive relaxation, psychotherapy; Alternative Medicine Systems:
Ayurveda, naturopathy, homeopathy, folk medicine; Energy therapy: healing
touch, energy therapy/reiki, Qi gong; Integrative Medicine Consult, Yoga, and
Exercise were stand-alone categories.
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baseline. Dietary supplements used by more than 10% of
participants at week 24 included vitamin D (81%), fish oil
(65%), magnesium (32%), green tea (24%), glucosamine
(19%), and turmeric (13%). The only changes from baseline
in proportion of patients using supplements were seen in
vitamin D, magnesium, and glucosamine (55%, 27%,
and 26% at baseline, respectively). The mean monthly
cost of supplements increased from $47 at baseline to
$72 at week 24.
Pain scores
The BPI is composed of four items that assess pain severity
and an additional seven questions that assess how the pain
interferes with life [8]. The composite score summarizes
the patient pain experience over the past 24 hours, with
1–4 rated as mild, 5–6 moderate, and 7–10 severe. The
mean baseline severity and interference scores in our
cohort were 4.7 (1.86) and 4.7 (2.53), respectively. The
overall model results for all three subgroups in both BPI
severity and BPI interference scales were statistically
significant (P < .001). Additionally, mean change scores
between baseline and any specific post-baseline study visit
for both BPI scales were significantly decreased (P < .001).
Figure 2 portrays the change in BPI scores over the study
duration. Mean severity scores decreased 23% from
moderate to mild at 24 weeks. Interference scores dropped
28% to a mean of 3.3 at week 24.
Depression, stress, and quality of life
Fifty-two percent of completers scored 16 or greater on
the CES-D at baseline, consistent with symptoms of de-
pression. As seen in Table 3, by week 24 the mean score
had dropped from 17.9 to 13.8 (median score decreased
from 16.0 to 11.0); at week 24, only 35% had scoresconsistent with depressive symptoms. Although both the
mental and physical component scores on the SF-12v2
remained below the U.S. norm of 50 at week 24, the
mean mental component score rose from 43.5 at baseline
to 46.5, and the mean physical component score rose from
37.7 at baseline to 41.5 at week 24 (P < .001). Similarly,
stress and fatigue decreased over time, and the participants’
sense of control increased (all P < .001).
The AIOS asks participants to summarize their sense
of well-being for the entire month by marking a point
on a plain line with an “X” somewhere between “Worst you
have ever been” and “Best you have ever been.” Participants’
sense of well-being increased significantly from a baseline
mean of 41.7 to 55.9 at week 24 (P < .001). To put these
values in context, rehabilitation center patients scored an
average of 33 and healthy controls a 61 on the AIOS [12].
Work productivity
The WPAI survey assesses the impact of an intervention
with respect to daily activity and productivity [13]. It has
been previously validated that overall work productivity is
significantly related to general health perceptions. The
WPAI survey was completed by the 145 participants who
reported having employment. The results (see Table 4)
demonstrate improvement in all parameters over the
24-week study period.
Laboratory studies
Specimens for hs-CRP and 25-hydroxyvitamin D were
obtained at baseline and at week 12. Mean hs-CRP
decreased from 4.0 (10.21) mg/L at baseline to 2.7 (6.55)
mg/L at 12 weeks.
The mean 25-hydroxyvitamin D level at baseline was 33.4
(17.05) ng/mL. At week 12, the mean value had increased
to 39.6 (16.68) ng/mL (P < .001). Considering >30 ng/mL as
the desirable range for 25-hydroxyvitamin D, 52% of the
participants were in the desirable range at baseline, and
70% were at week 12 [14].
Predictors of response
A multivariate logistic regression analysis showed that
patients with fewer years of chronic pain (p = 0.03), non-
Hispanic populations (p = 0.04), and those with higher
(worse) baseline BPI interference scores (p = 0.002) and
SF-12 physical component scores (p = 0.008) were more
likely to have a clinical meaningful response (i.e. ≥ 20
decrease in the BPI interference score over 24 weeks).
Age, gender, BMI, baseline SF-12 mental component
score, CES-D score, and PSS-4 score were not significant
predictors of response.
Discussion and conclusion
The initial project of the BraveNet practice-based research
network involved collection of a one-time questionnaire
Figure 1 Mosaic plot of Modalities received by Patients. The x-axis shows the number of modalities received and the width of the column is
proportional to the number of patients in each category – 1 modality (n = 22 patients), 2 modalities (n = 50), 3 modalities (n = 50), 4 modalities
(n = 52), 5 modalities (n = 42), 6 modalities (n = 19), 7 modalities (n = 5), all 8 modalities (n = 3). The y-axis shows the proportion of patients who
received each modality; the actual percentages are included in each colored box (where feasible).
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sites [6]. Building on the initial experience of collecting
data as a multi-site group, SIMTAP demonstrated our
ability to enroll participants and capture outcomes in a
prospective longitudinal study, requiring serial follow-up
data collection at three time points beyond baseline as well
as the ability to collect and process laboratory specimens.
The establishment of this functioning practice-based re-
search network in integrative medicine is one of the main
accomplishments of this endeavor.
We surpassed the target enrollment of 400, with 409
participants ultimately enrolled. Of these, 88 (21.5%) did
not contribute data at the six-week study visit. At
24 weeks, 66% of the enrolled participants were available
for follow-up. Chronic pain trials frequently encounterretention issues for a number of reasons, including the
nature of the population. It has been suggested that in a
typical 12-week, fixed-dose, placebo-controlled trial, a
dropout rate of 20%–50% is to be expected [15]. Our
participants received no financial incentives for their
participation in the 24-week study and, in fact, were
responsible for the cost of their integrative treatments. A
recent trial on a three-month yoga intervention versus
usual care for chronic back pain randomized 156 patients
to the yoga arm [16]. Of these, 93 (60%) attended at
least three of the first six sessions and at least three
others. Acknowledging the need to improve retention,
we conclude that within the context of chronic pain
intervention trials, the practice-based research network
is successful in recruiting and retaining patients who
Figure 2 Repeated-measures analysis of primary outcome: Brief Pain Inventory (BPI) pain scores. Reported P values are overall model
results summarizing any potential change across four time points throughout the study. Individual estimated change from baseline scores specify
changes in scores from baseline to any designated study visit on a scale from 0 to 10, with 0 indicating least possible pain or interference.
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on patient-reported outcomes of interest in a usual care
(non-efficacy) setting.
Our study demonstrates that an integrative approach
to treating chronic pain had a significant impact on pa-
tients’ pain as well as on associated symptoms and quality
of life. This success was in the context of long-standing
chronic pain, with an average duration in our sample of
greater than eight years. Whereas conventional medical





CES-D (0c–60) 17.9 (10.49) 16.1 (10.93) 15.9 (1
PSS-4 (0c–16) 6.7 (3.14) 6.2 (3.21) 5.9 (3
SF-12v2 mental (0–100c) 43.5 (10.44) 45.4 (10.34) 45.6 (1
SF-12v2 physical (0–100c) 37.7 (10.24) 39.4 (10.61) 40.7 (1
Quality of sleep (0–10c) 4.7 (2.91) 5.0 (2.95) 5.1 (2
Fatigue scale (0c–10) 5.8 (2.19) 5.4 (2.32) 5.2 (2
Sense of control (0–10c) 4.8 (2.47) 5.7 (2.28) 5.8 (2
CES-D: Center for Epidemiologic Studies Depression Scale; PSS-4: Perceived Stress S
aValues per study visit shown are means (SD); mean 24-week change from baseline
bP value indicates significant change from baseline and 24-week study visit if < .05;
cIndicates better health.
dIndicates improvement in health.focus on one outcome, integrative interventions have the
potential to affect multiple aspects of health and well-being
[17]. It has been recommended that additional patient-
recorded outcome measures are also important to monitor,
particularly in studies of chronic pain [18]. The trends in
decreased pain, stress, depression, and fatigue, and im-
provement in physical quality of life and overall well-being,
were consistent over the 24-week duration of the trial and
suggest the possibility of sustainable effects of the integra-







1.83) 13.8 (11.02) −4.0d <.001
.52) 6.1 (3.64) −1.1d <.001
0.67) 46.5 (10.97) 3.1d <.001
0.72) 41.5 (11.56) 3.7d <.001
.82) 5.3 (2.80) 0.7d <.001
.36) 4.9 (2.55) −0.8d <.001
.37) 6.1 (2.45) 1.3d <.001
cale-4; SF-12v2: 12-Item Short Form Health Survey.
values from repeated-measures analysis.
obtained from repeated-measures analysis.










Absenteeism (%) 8.5 (17.78) 7.8 (16.36) 4.9 (14.00) 5.1 (14.03) −3.6c .035
Presenteeism (%) 36.4 (23.54) 32.3 (25.09) 32.2 (26.12) 29.9 (27.99) −6.9c .002
Work productivity loss (%) 40.8 (25.07) 35.6 (27.67) 33.6 (26.76) 31.0 (28.96) −10.3c <.001
Activity impairment (%) 51.5 (27.64) 45.7 (26.86) 42.3 (27.67) 40.2 (29.80) −11.1c <.001
aPatients currently employed included in analysis (N = 145); values per study visit shown are means (SD); mean 24-week change from baseline values from
repeated-measures analysis.
bP value indicates significant change from baseline and 24-week study visit if < .05; obtained from repeated-measures analysis.
cIndicates improvement in health.
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is known about the challenges of treating chronic pain and
depression. In addition, findings on the WPAI survey sug-
gest that the improvements measured in patient-reported
outcomes also translated into greater productivity at work.
Predictors of response to an integrative medicine approach
included years of chronic pain, ethnicity, and baseline BPI
interference and SF-12 physical component scores.
We investigated hs-CRP as a general marker of in-
flammation rather than as a predictor of cardiac risk
[20,21]. The mean hs-CRP value declined one point,
suggesting a trend toward decreased inflammation. In
a previous study on musculoskeletal pain conducted at
our Minneapolis BraveNet site, 93% of the participants
were found to have insufficient levels of 25-hydroxyvitamin
D (≤20 ng/mL) [22]. To further assess the relationship of
hypovitaminosis D to pain, we included vitamin D levels
in SIMTAP. Our patients presented with baseline vitamin
D levels higher than those seen in the prior study and in
the average American adult [21,23]. This likely reflects
awareness among both patients and practitioners of the
increasing importance of adequate vitamin D levels. The
findings that 70% of SIMTAP participants had values greater
than 30 ng/mL and none were deficient at week 12 reflect
the serious attention paid to maintaining sufficient vitamin
D in integrative medicine practices.
Limitations
One limitation of this study is the loss to follow-up. Our re-
sults describe the outcomes of 252 participants at nine sites
who completed all study visits during the 24-week integra-
tive medicine intervention for chronic pain. It could be
argued that these completers were somehow different from
the noncompleters, skewing the final study results, although
this notion is not supported by the sensitivity analysis. The
bulk of patients lost failed to return for the first study
follow-up at week six. This may represent patients who were
“shopping” for a new approach for their chronic pain, visited
one of the centers, enrolled in SIMTAP, and then chose not
to return for follow-up care. The 252 completers can be
considered as being treated “on protocol” for analysis in this
prospective non-randomized open-label intervention.A second limitation is the absence of a control group.
It could be argued that the significant benefits we observed
in SIMTAP participants may have nothing to do with the
integrative intervention per se. Because we did not control
for natural history and the passage of time, we cannot
estimate what proportion of the observed benefits would
have occurred separately from the intervention themselves.
Without a control group of equal attention, it could be ar-
gued that the benefits observed were related to the degree
of attention participants received at our centers. Because
one of our goals was to assist in the development of our
practice-based research network and to demonstrate that
we could recruit, follow, and retain participants, as well as
collect and process laboratory specimens, we opted not to
include randomization or comparison to a control group
in our design.
In the spirit of the individualized care that characterizes
the integrative medicine approach to the unique individual,
we did not mandate a standardized intervention for all
SIMTAP participants. Although this makes it more difficult
to define the precise treatment that patients received,
the network felt that the personalized treatment plan
was preferred. Practitioners of traditional Chinese medicine
generally devise individualized treatment plans based
on each patient’s unique diagnosis rather than follow a
standard intervention based on the complaint. In a
seminal randomized controlled trial of Chinese herbal
medicine for treatment of irritable bowel syndrome,
investigators compared a standard and an individualized
Chinese herbal formulation to a placebo [24]. Results
showed that compared with patients in the placebo group,
patients in the two active treatment groups had improve-
ments in bowel symptoms as rated by both the patients
and their gastroenterologists at the end of the 16-week
intervention. However, at follow-up 14 weeks after com-
pletion of the treatment, only the individualized herbal
medicine treatment group maintained improvement.
Future directions
The results of SIMTAP suggest that the tailored, multi-
modal approach to treating chronic pain combining con-
ventional and complementary therapies improves quality
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The components of integrative medicine that contrib-
ute to improving patients’ physical and emotional
health require further research since this study is not
powered to compare the effectiveness of different com-
binations to each other. In addition, a comparison of
integrative medicine to usual care would help define
the effectiveness of different treatment approaches to
chronic pain.
Investigating the therapeutic impact of a “whole systems”
approach such as our integrative intervention is a daunting
challenge, as funding agencies are accustomed to a more
reductionist approach to assessing which individual com-
ponent of a multimodality intervention is the active one. In
addition, the conventional approach would be to deliver a
standardized intervention to all study participants. These
conventions run counter to the philosophy of integrative
medicine, which places the needs of the unique person
seeking care first and designs an appropriate personal-
ized intervention based on the individual’s assessment,
much akin to practitioners of traditional Eastern medicine.
New initiatives, such as the Patient Reported Outcome
Measurement Information System and the Patient-Centered
Outcomes Research Institute, will hopefully have an
impact in advancing research of integrative medicine
interventions [25-28].
The 2010 Patient Protection and Affordable Care Act
required the Department of Health and Human Services
to enlist the Institute of Medicine in examining pain as a
public health problem. The recommendations from the
institute suggest that among the “steps to improving care,
healthcare providers should increasingly aim at tailoring
pain care to each person’s experience, and self-management
of pain should be promoted” [1]. Although it is often easier
and faster to respond to the patient presenting with chronic
pain by writing a prescription, increasingly for a substance
with addictive potential, an integrative medicine approach
may more closely approximate the Institute of Medicine’s
blueprint for transforming health care.
Abbreviations
AIOS: Arizona Integrative Outcomes Scale; BPI: Brief Pain Inventory;
BraveNet: Bravewell Integrative Medicine Research Network; CES-D: Center
for Epidemiologic Studies Depression Scale; hs-CRP: high-sensitivity
C-reactive protein; PSS-4: Perceived Stress Scale-4; SF-12v2: 12-Item Short
Form Health Survey; SIMTAP: Study on Integrative Medicine Treatment
Approaches for Pain; WPAI: Work Productivity and Activity Impairment.
Competing interests
CP is a consultant to the Bravewell Collaborative, which funded the creation
of BraveNet and this study. The other authors declare that they have no
competing interests.
Authors’ contributions
All authors participated in the conception and design of the study. DIA, RD,
RR, RQW carried out the analyses and drafted the manuscript. All authors
read and approved the final manuscript.Acknowledgements
None of this would have been possible without the vision and generous
support of the Bravewell Collaborative, which funded the creation of
BraveNet and this study. The Bravewell Collaborative played no role in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or approval of the manuscript;
and decision to submit the manuscript for publication. We are indebted to
our participants for their invaluable contributions to this project. We are also
grateful to our site collaborators who contributed enormously to the success
of the study: Alliance Institute for Integrative Medicine: Betsy Lorenzi, RN;
University of Maryland School of Medicine: Elizabeth Kimbrough, PhD, MPH,
and Deborah Taber, BA; Continuum Center for Health and Healing: Jeanne
Kenney, RN, and Peter Homel, PhD; Duke Integrative Medicine: Shin-Yiing
Yeung, BS, and Jessica Wakefield, MA; Penny George Institute for Health and
Healing: Lori Knutson, RN, BSN, HNC, and Desiree Trebesch, MA; Myrna Brind
Center of Integrative Medicine: Michael Mathews and Nancy Wintering,
MSW; UCSF Osher Center for Integrative Medicine: Steffanie Goodman, MPH;
Scripps Center for Integrative Medicine: Eva Stuart, RN; and the Venice Family
Clinic: Nancy Rodriguez. Thanks to Peter Hoffmann for his editorial assistance.
Special gratitude to Gayle Paynter and Ron Roddy, Duke Clinical Research
Institute, for successfully managing this multicenter project.
Author details
1UCSF Osher Center for Integrative Medicine, University of California San
Francisco, 1545 Divisadero Street, 4th Floor, San Francisco, CA 94115, USA.
2Duke Clinical Research Institute, Duke University Health System, Durham,
NC, USA. 3Bravewell Collaborative, Minneapolis, MN, USA. 4Penny George
Institute for Health and Healing, Allina Health, Minneapolis, MN, USA.
5Alliance Institute for Integrative Medicine, Cincinnati, OH, USA. 6Myrna Brind
Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, PA,
USA. 7University of Maryland School of Medicine, Baltimore, MD, USA.
8Scripps Center for Integrative Medicine, La Jolla, CA, USA. 9Continuum
Center for Health and Healing, Beth Israel Medical Center, New York, NY,
USA. 10Venice Family Clinic, Venice, CA, USA. 11Duke Integrative Medicine,
Duke University Health System, Durham, NC, USA.
Received: 28 October 2012 Accepted: 12 June 2013
Published: 24 June 2013
References
1. Institute of Medicine: Relieving Pain in America: A Blueprint for Transforming
Prevention, Care, Education, and Research. Washington, DC: National
Academies Press; 2011.
2. Nahin RL, Barnes PM, Stussman BJ, Bloom B: Costs of complementary and
alternative medicine (CAM) and frequency of visits to CAM practitioners:
United States. Natl Health Stat Report 2007, 2009(18):1–14.
3. AARP and National Center for Complementary and Alternative Medicine:
Complementary and Alternative Medicine: What People Aged 50 and Older Discuss
With Their Health Care Providers. Consumer Survey Report; 2010. http://nccam.
nih.gov/news/camstats/2010/introduction.htm. Accessed June 29, 2012.
4. Chou R, Huffman LH, American Pain Society; American College of
Physicians: Nonpharmacologic therapies for acute and chronic low
back pain: a review of the evidence for an American Pain Society/
American College of Physicians clinical practice guideline. Ann Intern
Med 2007, 147(7):492–504.
5. Kligler B, Maizes V, Schachter S, Park CM, Gaudet T, Benn R, Lee R, Remen
RN, Education Working Group, Consortium of Academic Health Centers for
Integrative Medicine: Core competencies in integrative medicine for
medical school curricula: a proposal. Acad Med 2004, 79(6):521–531.
6. Wolever RQ, Abrams DI, Kligler B, Frye J, Edman JS, Amoils S, Dusek J,
Pradham E, Roberts R, Spar M, Gaudet T, Guarneri M, Homel P, Amoils S, Lee
RA, Monti DA, Berman B, Dolor R: Patients seek integrative medicine for
preventive approach to care. Explore. in press.
7. Horrigan B, Lewis S, Abrams D, Pechura C: Integrative medicine in
America: How integrative medicine is being practiced in clinical centers
across the United States. Glob Adv Health Med. 2012; 1(3):18-94.
8. Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994, 23(2):129–138.
9. Ware J, Kosinski M, Keller SD: A 12-item short form health survey:
construction of scales and preliminary tests of reliability and validity.
Med Care 1996, 34(3):220–233.
Abrams et al. BMC Complementary and Alternative Medicine 2013, 13:146 Page 9 of 9
http://www.biomedcentral.com/1472-6882/13/14610. Radloff LS: The CES-D scale: a self-report depression scale for research in
the general population. Appl Psychol Meas 1977, 1(3):385–401.
11. Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress.
J Health Soc Behav 1983, 24(4):385–396.
12. Bell IR, Cunningham V, Caspi O, Meek P, Ferro L: Development and
validation of a new global well-being outcomes rating scale for
integrative medicine research. BMC Complement Altern Med 2004,
4:1–10.
13. Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work
productivity and activity impairment instrument. Pharmacoeconomics 1993,
4(5):353–365.
14. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney
RP, Murad MH, Weaver CM, Endocrine Society: Evaluation, treatment, and
prevention of vitamin D deficiency: an Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab 2011, 96(7):1911–1930.
15. Kim Y: Missing data handling in chronic pain trials. J Biopharm Stat 2011,
21(2):311–325.
16. Tilbrook HE, Cox H, Hewitt CE, Kang’ombe AR, Chuang LH, Jayakody S, Aplin
JD, Semlyen A, Trewhela A, Watt I, Torgereson DJ: Yoga for chronic low
back pain: a randomized trial. Ann Intern Med 2011, 155(9):569–578.
17. Eton DT, Bauer BA, Sood A, Yost KJ, Sloan JA: Patient-reported outcomes
in studies of complementary and alternative medicine: problems,
solutions, and future directions. Explore 2011, 7(5):314–319.
18. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns
RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R,
Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG,
McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP,
Rothman M, Royal MA, Simon L, et al: Core outcome measures for chronic
pain clinical trials: IMMPACT recommendations. Pain 2005, 113(1–2):9–19.
19. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT,
Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke
LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR,
Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP,
McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al: Interpreting the
clinical importance of treatment outcomes in chronic pain clinical trials:
IMMPACT recommendations. J Pain 2008, 9(2):105–121.
20. Libby P: Inflammation in atherosclerosis. Nature 2002, 420(6917):868–874.
21. Amer M, Qayyum R: Relation between serum 25-hydroxyvitamin D and
C-reactive protein in asymptomatic adults (from the continuous National
Health and Nutrition Examination Survey 2001 to 2006). Am J Cardiol
2012, 109(2):226–230.
22. Plotnikoff GA, Quigley JM: Prevalence of severe hypovitaminosis D in
patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc
2003, 78(12):1463–1470.
23. Yetley EA: Assessing the vitamin D status of the US population. Am J Clin
Nutr 2008, 88(2):558S–564S.
24. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M: Treatment of
irritable bowel syndrome with Chinese herbal medicine: a randomized
controlled trial. JAMA 1998, 280(18):1585–1589.
25. National Institutes of Health: PROMIS: Patient-Reported Outcomes Measurement
Information System. http://www.nihpromis.org. Accessed June 29, 2012.
26. Garcia SF, Cella D, Clausner SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW,
Stone AA, Weinfurt K: Standardizing patient-reported outcomes assessment
in cancer clinical trials: a patient-reported outcomes measurement
information system initiative. J Clin Oncol 2007, 25(32):5106–5112.
27. Selby JV, Beal AC, Frank L: The Patient-Centered Outcomes Research
Institute (PCORI) national priorities for research and initial research
agenda. JAMA 2012, 307(15):1583–1584.
28. Methodology Committee of the Patient-Centered Outcomes Research
Institute (PCORI): Methodological standards and patient-centeredness in
comparative effectiveness research: the PCORI perspective. JAMA 2012,
307(15):1636–1640.
doi:10.1186/1472-6882-13-146
Cite this article as: Abrams et al.: The BraveNet prospective
observational study on integrative medicine treatment approaches for
pain. BMC Complementary and Alternative Medicine 2013 13:146.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
